Delaware confirms Vancomycin-resistant Staphylococcus aureus case
The individual, who has a wide range of underlying health conditions, is being treated on an outpatient basis and is expected to recover.
VRSA is rare. It is afflicts people who come into contact with Staphylococcus aureus and then the bacteria mutates to become resistant to the antibiotic Vancomycin, which is usually used to treat the staph infections.
VRSA is treatable with other antibiotics, but because the mutated bacteria is also resistant to other medicines, it is a difficult and complicated process.
Certain variables make people more susceptible to contracting VRSA, including Vancomycin-resistant enterococcal infections, Methicillin-resistant Staphylococcus aureus, previous treatments with Vancomyin, or underlying conditions such as diabetes and chronic skin ulcers.
The VRSA case was confirmed on March 10 at the U.S. Centers for Disease Control and Prevention lab. This is the 14th VRSA case confirmed within the United States. Health professionals in Delaware previously confirmed two VRSA cases in 2010 and one case in 2012. The DPH does not believe that there is a connection between the four cases.